The Mechanism of MicroRNAs Network in Alzheimer's Disease (MicroRNAs AD)

September 21, 2021 updated by: Shanghai Mental Health Center

Shanghai Mental Health Center

MicroRNAs network, such as MicRNA107 et al, regulate the pathology of Alzheimer's disease and the clinical validation in diagnosis AD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shanghai
      • Shanghai, Shanghai, China, 200030
        • Department of Psychogeriatrics,Shanghai Mental Health Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

age between 60 to 90 years old.

Description

Inclusion Criteria:

  • NIA-AA MCI due to AD clinical criteria for MCI due to AD
  • NIA-AA AD clinical criteria for AD

Exclusion Criteria:

  • Other type of dementia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Normal elderly
normal cognitive group
plasma micRNAs concentration
aMCI
amnestic mild cognitive impairment
plasma micRNAs concentration
AD
Alzhiemer's disease
plasma micRNAs concentration

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MicRNAs diagnosis validation for aMCI
Time Frame: 5 years
MicRNAs concentration in plasma among three groups
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2016

Primary Completion (Actual)

December 31, 2019

Study Completion (Actual)

December 31, 2019

Study Registration Dates

First Submitted

January 8, 2020

First Submitted That Met QC Criteria

September 21, 2021

First Posted (Actual)

September 24, 2021

Study Record Updates

Last Update Posted (Actual)

September 24, 2021

Last Update Submitted That Met QC Criteria

September 21, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on MicRNAs test

3
Subscribe